Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors
- 851 Downloads
The aim of this study was to evaluate the efficacy of fractional CO2 laser therapy in breast cancer survivors as a therapeutic method for vulvovaginal atrophy (VVA) dyspareunia.
50 patients (mean age 53.3 years) underwent fractional microablative CO2 laser treatment for dyspareunia in oncological menopause (mean time of menopause 6.6 years). The Gloria Bachmann’s Vaginal Health Index (VHI) score was chosen as system to evaluate the presence of VVA and its improvement after the treatment. Intensity of dyspareunia was evaluated using a visual analog scale (VAS).
Data indicated a significant improvement in VVA dyspareunia (p < 1.86e−22) in breast cancer survivors who had undergone 3 sessions of vaginal fractional CO2 laser treatment. Moreover, VHI scores were significantly higher 30 days post-treatment (T4) (p < 0.0001). 76 % of patients were satisfied or very satisfied with the treatment results. The majority (52 %) of patients were satisfied after a long-term follow-up (mean time 11 months). No adverse events due to fractional CO2 laser treatment occurred.
The treatment with fractionated CO2 laser appeared to be a feasible and effective treatment for VVA dyspareunia in breast cancer survivors with contraindications to hormonal treatments.
KeywordsVulvovaginal atrophy Laser Oncological menopause Breast cancer survivors
We thank DEKA M.E.L.A. S.r.l. for technical support.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 7.Salvatore S, Nappi RE, Zerbinati N, Calligaro A, Ferrero S, Origoni M, Candiani M, Leone Roberti Maggiore U (2014) A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. Climateri 17:363–369Google Scholar
- 8.Committee on Gynecologic Practice, American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 378 (2007) Vaginal “rejuvenation” and cosmetic vaginal procedures. Obstet Gynecol 110:737–738Google Scholar
- 11.Persu C, Chapple CR, Cauni, V, Gutue S, Geavlete P (2011) Pelvic organ prolapse quantification system (POP–Q)—a new era in pelvic prolapsed staging. J Med Life 75–81Google Scholar
- 12.Bachmann GA, Notevolitz M, Kelly SL (1992) Long-term non-hormonal treatment of vaginal dryness. Clin Pract Sex 8:3–8Google Scholar
- 15.Portman D, Palacios S, Nappi RE, Mueck AO (2014) Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial. Maturitas 78:91–98CrossRefPubMedGoogle Scholar
- 16.Gaspar A, Addamo G, Brandi H (2011) Vaginal fractional CO2 laser: a minimally invasive option for vaginal rejuvenation. Am J Cosm Surg 28:156–162Google Scholar